Literature DB >> 15920323

Refractory ascites.

Andrés Cárdenas1, Vicente Arroyo.   

Abstract

Patients with cirrhosis have significant abnormalities in their fluid and electrolyte balance; this is manifested mainly by the development of ascites and edema. Ascites is the most common complication of patients with cirrhosis and its development constitutes the first and most important manifestation of the disease. With disease progression, patients with advanced cirrhosis and severe urinary sodium retention develop refractory ascites, a condition in which patients do not respond to diuretics or develop severe side effects to these that preclude their use. This condition occurs in 5-10% of cases admitted to the hospital for treatment of ascites. Approximately half of these patients will die within 1 year if not transplanted; therefore, the best therapy is liver transplantation in suitable candidates. During the last two decades, significant advances have been made in regard to pathogenesis and treatment of refractory ascites. The re-introduction of therapeutic paracentesis with plasma expansion in the 1980s was a milestone in the treatment of these patients. In addition, the introduction of transjugular intrahepatic portosystemic shunts as a therapy for refractory ascites has certainly provided a reasonable alternative for those patients with preserved liver function and unwilling to undergo several taps per month. This article will discuss the pathophysiology, clinical features and therapy of refractory ascites in cirrhosis. 2005 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2005        PMID: 15920323     DOI: 10.1159/000084723

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  10 in total

1.  Treatment of refractory ascites.

Authors:  Praveena G Velamati; H Franklin Herlong
Journal:  Curr Treat Options Gastroenterol       Date:  2006

2.  Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.

Authors:  Ai Nakagawa; Masanori Atsukawa; Akihito Tsubota; Chisa Kondo; Tomomi Okubo; Taeang Arai; Norio Itokawa; Yoshiyuki Narahara; Katsuhiko Iwakiri
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

3.  Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.

Authors:  Tadashi Namisaki; Yuki Tsuji; Mitsuteru Kitade; Nobuyuki Yorioka; Yukihisa Fujinaga; Yasuhiko Sawada; Norihisa Nishimura; Koh Kitagawa; Takashi Inoue; Hiroaki Takaya; Kosuke Kaji; Hideto Kawaratani; Kei Moriya; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

4.  Automated low flow pump system for the treatment of refractory ascites: a single-center experience.

Authors:  M N Thomas; G H Sauter; A L Gerbes; M Stangl; T S Schiergens; M Angele; J Werner; M Guba
Journal:  Langenbecks Arch Surg       Date:  2015-11-13       Impact factor: 3.445

5.  Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity.

Authors:  Ankur Varma; Susan C Abraham; Rohtesh S Mehta; Neeraj Y Saini; Medhavi Honhar; Munazza Rashid; Julianne Chen; Samer A Srour; Qaiser Bashir; Gabriela Rondon; Betul Oran; Chitra M Hosing; Yago Nieto; Partow Kebriaei; Amin M Alousi; Sairah Ahmed; David Marin; Issa F Khouri; Stefan O Ciurea; Muzaffar H Qazilbash; Katy Rezvani; Paolo Anderlini; Borje S Andersson; Elizabeth J Shpall; Richard E Champlin; Uday R Popat
Journal:  Blood Adv       Date:  2020-04-14

6.  The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.

Authors:  Long Yan; Feng Xie; Jiongjiong Lu; Qingqiang Ni; Changying Shi; Caixi Tang; Jiamei Yang
Journal:  BMC Gastroenterol       Date:  2015-06-09       Impact factor: 3.067

7.  Clinical Profile and Complications of Paracentesis in Refractory Ascites Patients With Cirrhosis.

Authors:  Sreenivasa Rao Sudulagunta; Mahesh Babu Sodalagunta; Shiva Kumar Bangalore Raja; Hadi Khorram; Mona Sepehrar; Zahra Noroozpour
Journal:  Gastroenterology Res       Date:  2015-07-22

8.  Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model.

Authors:  Norikazu Tanabe; Taro Takami; Koichi Fujisawa; Toshihiko Matsumoto; Naoki Yamamoto; Isao Sakaida
Journal:  J Clin Biochem Nutr       Date:  2017-05-16       Impact factor: 3.114

9.  Refractory ascites-the contemporary view on pathogenesis and therapy.

Authors:  Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  PeerJ       Date:  2019-10-15       Impact factor: 2.984

10.  Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation.

Authors:  Ju Hee Seo; Seung Up Kim; Jun Yong Park; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.